NovalGen appoints Dr Michael Owen and Mr Scott Clarke to the Board of Directors

NovalGen, a biopharmaceutical company developing breakthrough cancer therapies, alongside a disruptive auto-regulation platform, has announced the appointment of Dr Michael Owen and Mr Scott Clarke as Non-Executive Directors to its Board, effective January 2023.

“Both Mike and Scott are highly experienced industry executives who bring a wealth of leadership and drug development experience, and they will be an asset to our Board of Directors,”said Professor Amit Nathwani, Founder and CEO of NovalGen. “NovalGen is at a transformational stage in its development as we progress our lead product through the clinic as well as drive our pre-clinical programmes, including our first-in-class half-life extended T cell engager targeting ROR-1 with autoregulation capability, which demonstrates the inherent value in both our pipeline and our technology base.”

Read the full story from NovalGen.